TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Assisted patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: False positive rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: increase in reciprocal steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of participant enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motivation reported by participants
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in symptoms of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strengthening coping self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: favorable symptom reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trouble breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: interference with activity scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VMR increase after L-arginine infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of any adverse clinical event
Endpoint domain: Adverse events/effects
Primary endpoint: Dislodgment force of airway devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels after epidural catheter insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain scores during epidural catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total YMRS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean salvaged tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with pain therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pain outcomes
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: prevention of preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fracture resistance of root dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Emotional condition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interstitial SM glycerol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in emergence reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in retching-vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean minute ventilation at PetCO2 = 55 mmHg (V(E55))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median total AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resolution of OSA (AHI < 5 events/hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change-from-baseline QTcI (ΔQTcI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunogenicity of 'Grifor' vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of 'Grifor' vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Non-reactogenicity of 'Grifor' vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in hot flush score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: habituation of ASR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: susceptibility to peripheral distracters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: slower initiation of inhibitory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Need for sedation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Agreement between hand held device and standard echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Misdiagnosis of patients with tricuspid regurgitation
Endpoint domain: Adverse events/effects
Primary endpoint: mean intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of suicidal thoughts
Endpoint domain: Mortality/survival
Primary endpoint: Lifetime prevalence of suicidal thoughts
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of psychiatric disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Technical skills scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophil numbers in mannitol-induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of IL-8 in mannitol-induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of breakthrough pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of congestive heart failure until 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality after 6 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Complete ST resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average visual analogue scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total treatment efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median overall-survival
Endpoint domain: Mortality/survival
Primary endpoint: cumulative chest drain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of chest tubes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in acute clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: ABH loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative CAL changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate on PVB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical site infection (SSI) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total cost of SSI prophylaxis and treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ischemic heart death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in movement skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in fruit and vegetable serves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in BMI Z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: combined outcome mortality and BPD
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of EIS examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of EIS examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma clearance variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of distribution variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration predictability accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prescription rates for alendronate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in prescription rates for metformin
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in prescription rates for alpha1-blockers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in prescription rates for finasteride
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total stroke risk
Endpoint domain: Mortality/survival
Primary endpoint: Motivation to perform exercises
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perception of ambient light glare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adiponectin to Leptin (A/L) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD4+ T-cell count gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load undetectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point-prevalence abstinence rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decline of 50% or more on HDRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panic frequency and severity of agoraphobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median peak injection pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture resistance of the tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in health knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in nutrient intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in office and average 24-h blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in resting MSNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in MSNA responses during OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of embolic material
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total area of embolic particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rejection episode rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pharyngeal airway space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in thickness of rectal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in number of mitoses per mucosal crypt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in crypt surface area of rectal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: endoscopic visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for chromoendoscopic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial or complete T2DM remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in diabetes medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in percentage of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in medial loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDA and carbonyl levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma docosahexaenoic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ileal amino acid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5 times sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent reduction in average pain for the past 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGIC analysis of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cortical positivity in auditory condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stool frequency per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharmacokinetic similarity (AUCinf and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measurements during insertion of the Foley catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission to hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drained volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Residual urinary output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reaction rate to codeine
Endpoint domain: Adverse events/effects
Primary endpoint: annual rate of change in albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Root sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction with outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximal fall in peak expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of pediculosis capitis infestation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood aspartate transaminase levels on day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Caspase-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apoptotic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of anesthesia block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Antiviral therapy initiation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Levels of ω‐3 fatty acids in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: loss of less than 3 lines of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of nifedipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentrations of nifedipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag-time in nifedipine absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine secretion from tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insulin Sensitivity (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Waist to Height Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BOLD signal changes in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Melatonin levels (pg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-endorphin plasma levels (pmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of sleep assessed clinically
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: wound infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Learning advantage in acquisition, maintenance, and generalization of grammatical forms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to perform daily living activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recourse to rehabilitation treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants with undetectable plasma HIV-1 RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CD4 T-cell count increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intracranial haemorrhage/periventricular leukomalacia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HrQoL improvements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment completion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time per dose
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost incurred on treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: postexercise systolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: atrial natriuretic peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DBS responses using clinical rating scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent upright reflux episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: belching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: A1C of less than 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic blood pressure less than 130 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall duct clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate at 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Complications during follow up
Endpoint domain: Adverse events/effects
Primary endpoint: FEV1-av
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cervical flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Left lateral-flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skindex-16 values
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: No longer fulfilled diagnostic criteria for anxiety disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance from the whole lung during cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: clearance from the whole lung during FET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: glycaemic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: in vitro digestibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tandem balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new stroke events
Endpoint domain: Mortality/survival
Primary endpoint: LV ejection fraction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV end-systolic volume index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cognitive test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: verbal fluency impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ratings of general satisfaction 2 months postdelivery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pre-CPB hemodynamic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per patient of opioids
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidence of significant vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: transformation to myelofibrosis, acute myeloid leukemia, or myelodysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes